A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis

Trial Profile

A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan
  • Indications Amyloidosis
  • Focus Therapeutic Use
  • Acronyms EMN-03
  • Most Recent Events

    • 06 Dec 2016 Primary endpoint has been met. (Overall hematologic response at 3 months) as per results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Aug 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top